HeyJaredGargi Mukherjee
- Indexed articles, last 90 days
- 44
- Latest publication
- Sep 9, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Allo-HSCT Shows Long-Term Benefit in Hepatosplenic Lymphoma (opens the original)
Read excerpt
At 3 years, more than half of patients with hepatosplenic T-cell lymphoma who underwent allogeneic hematopoietic stem cell transplantation (HSCT) were alive, according to a retrospective study. Lactate dehydrogenase at or below the upper limit of normal at diagnosis and complete remission before transplantation were both associated with significantly better survival outcomes. In patients receiving autologous transplantation, relapse occurred in 50% by 3 years, despite the majority being in compl
Does Pediatric ALL Therapy Work Long-Term in Young Adults? (opens the original)
Read excerpt
A pediatric-inspired chemotherapy regimen was associated with a durable survival benefit in adolescents and young adults with Philadelphia chromosome-negative (Ph-negative) acute lymphoblastic leukemia (ALL), according to the 10-year follow-up of the CALGB 10403 study. Late relapses were uncommon, occurring mainly in patients with B-cell ALL. However, less than 40% of patients completed planned therapy because of toxicity or nonadherence. “These long-term findings underscore the importance of ea
Gepotidacin as Effective as Standard Therapy for Gonorrhea (opens the original)
Read excerpt
Oral gepotidacin demonstrated high treatment success rates for uncomplicated urogenital gonorrhea, with nucleic acid amplification test (NAAT)-confirmed success rates similar to those of ceftriaxone plus azithromycin. Baseline concordance between NAAT and culture results was high at 98.4%, supporting NAAT as a complementary diagnostic tool in future gonorrhea clinical trials. “[T]reatment success rates determined by NAAT at the urogenital site were high and similar following treatment with gepot
Early Step-Down Safe, Cost-Effective in Stable Candidiasis (opens the original)
Read excerpt
Early antifungal de-escalation (DES) from an echinocandin to an azole within 5 days was safe and not associated with worse 30-day outcomes in clinically stable patients with invasive candidiasis who had adequate source control. It also reduced drug costs by more than half, particularly among those with candidemia. “In adult patients with IC [invasive candidiasis] who were clinically stable and had adequate source control, early DES (≤ 5 days) was safe and not associated with worse clinical outco
Does Maintenance Therapy Extend Life in mCRC? (opens the original)
Read excerpt
Maintenance therapy was associated with longer overall survival (OS) than active surveillance in patients with metastatic colorectal cancer (mCRC) who achieved disease control after first-line bevacizumab-based combination chemotherapy. However, this association was not maintained after adjustment for baseline prognostic factors, suggesting that baseline differences may have contributed to the observed survival advantage. "These real-world data suggest a potential survival advantage associated w
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.